Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie's (ABBV) Humira Drug Label Update Approved by FDA

by Zacks Equity Research

AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira

    Arpita Dutt headshot

    Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?

    by Arpita Dutt

    Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.

      Roche's Rituxan Gets FDA Advisory Committee's Recommendation

      by Zacks Equity Research

      Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.

        Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

        by Zacks Equity Research

        Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

          AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA

          by Zacks Equity Research

          AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation

            AstraZeneca's Lung Cancer Drug Tagrisso Approved in China

            by Zacks Equity Research

            AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.

              Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

              by Zacks Equity Research

              Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

                by Zacks Equity Research

                Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

                  Should Value Investors Pick Roche Holding (RHHBY)?

                  by Zacks Equity Research

                  Roche Holding (RHHBY) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                    Inovio (INO) Q4 Loss Wider than Expected; Shares Decline

                    by Zacks Equity Research

                    Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.

                      Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                      by Zacks Equity Research

                      Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                        Arpita Dutt headshot

                        How Incyte Stock Became a Bull Market Star for Biotech Investors

                        by Arpita Dutt

                        Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

                          Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates

                          by Zacks Equity Research

                          Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.

                            Can Epizyme (EPZM) Spring a Surprise This Earnings Season?

                            by Zacks Equity Research

                            Epizyme, Inc. (EPZM) is scheduled to report fourth-quarter 2016 results on Mar 9, before the opening bell.

                              The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

                                Arpita Dutt headshot

                                5 FDA Decisions to Watch Out for in Mar 2017

                                by Arpita Dutt

                                Companies like Merck (MRK) are awaiting key FDA decisions this month.

                                  What's in Store for Immune Design (IMDZ) in Q4 Earnings?

                                  by Zacks Equity Research

                                  Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug

                                    by Arpita Dutt

                                    Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.

                                      Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View

                                      by Zacks Equity Research

                                      Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.

                                        Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data

                                        by Zacks Equity Research

                                        Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.

                                          Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

                                          by Zacks Equity Research

                                          Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                                            Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

                                            by Zacks Equity Research

                                            Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

                                              Prothena (PRTA) Reports Wider-than-Expected Loss in Q4

                                              by Zacks Equity Research

                                              Prothena's wider-than-expected loss in the fourth quarter was disappointing.

                                                Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                                                by Zacks Equity Research

                                                Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.

                                                  Kinjel Shah headshot

                                                  Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

                                                  by Kinjel Shah

                                                  Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.